ENDOGLIN (CD105): A marker of tumour vasculature for assessment of malignant potential of oral submucous fibrosis.

Q3 Medicine

Journal of Oral and Maxillofacial Pathology Pub Date : 2024-10-01 Epub Date: 2024-12-31 DOI:10.4103/jomfp.jomfp_67_24

Subraj Shetty, Treville Pereira, Sandhya Tamgadge, Sandeep Kale, Pooja Kamat, Sourab Kumar

{"title":"ENDOGLIN (CD105): A marker of tumour vasculature for assessment of malignant potential of oral submucous fibrosis.","authors":"Subraj Shetty, Treville Pereira, Sandhya Tamgadge, Sandeep Kale, Pooja Kamat, Sourab Kumar","doi":"10.4103/jomfp.jomfp_67_24","DOIUrl":null,"url":null,"abstract":"Background: Oral submucous fibrosis (OSMF) is a precancerous condition associated with the use of betel/areca nut in various forms. It is characterized by restricted mouth opening, tongue protrusion and cheek rigidity. Oral submucous fibrosis, is primarily prevalent among the people of the Indian subcontinent and it has been reported that about one third of the OSMF patients develop squamous cell carcinoma.Endoglin (CD-105) is a hypoxia induced protein and a potential marker for activated endothelial cells which signify tumorigenic neoangiogenesis.Aim: To determine expression of CD105 and study relation of neoangiogenesis with the clinical staging and histopathological grading of oral submucous fibrosis.Material and method: Immunohistochemical expression of CD105 was evaluated on forty nine (49) paraffin-embedded tissue sections of diagnosed cases of OSF and seven (7) control samples of healthy volunteers.Results: There were 13 cases in Stage A, 11 cases in Stage B, 13 cases in Stage C, and 12 cases in Stage D. There were 4 cases in Grade 1 (Very early), 19 cases in Grade 2 (Early), 19 cases in Grade 3 (Moderately advance) and 7 cases in Grade 4 (Advance).Conclusion: The present study was first immunohistochemical study to demonstrate MVD, MVP and MVAP with CD105 expression in OSMF cases. However, well-designed studies with larger sample size is required to validate CD105 as a reliable biomarker for malignant transformation in future research.","PeriodicalId":38846,"journal":{"name":"Journal of Oral and Maxillofacial Pathology","volume":"28 4","pages":"589-595"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11819617/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oral and Maxillofacial Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jomfp.jomfp_67_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/31 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Oral submucous fibrosis (OSMF) is a precancerous condition associated with the use of betel/areca nut in various forms. It is characterized by restricted mouth opening, tongue protrusion and cheek rigidity. Oral submucous fibrosis, is primarily prevalent among the people of the Indian subcontinent and it has been reported that about one third of the OSMF patients develop squamous cell carcinoma.Endoglin (CD-105) is a hypoxia induced protein and a potential marker for activated endothelial cells which signify tumorigenic neoangiogenesis.

Aim: To determine expression of CD105 and study relation of neoangiogenesis with the clinical staging and histopathological grading of oral submucous fibrosis.

Material and method: Immunohistochemical expression of CD105 was evaluated on forty nine (49) paraffin-embedded tissue sections of diagnosed cases of OSF and seven (7) control samples of healthy volunteers.

Results: There were 13 cases in Stage A, 11 cases in Stage B, 13 cases in Stage C, and 12 cases in Stage D. There were 4 cases in Grade 1 (Very early), 19 cases in Grade 2 (Early), 19 cases in Grade 3 (Moderately advance) and 7 cases in Grade 4 (Advance).

Conclusion: The present study was first immunohistochemical study to demonstrate MVD, MVP and MVAP with CD105 expression in OSMF cases. However, well-designed studies with larger sample size is required to validate CD105 as a reliable biomarker for malignant transformation in future research.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Oral and Maxillofacial Pathology Medicine-Otorhinolaryngology

CiteScore

1.40

自引率

0.00%

发文量

115

期刊介绍： The journal of Oral and Maxillofacial Pathology [ISSN:print-(0973-029X, online-1998-393X)] is a tri-annual journal published on behalf of “The Indian Association of Oral and Maxillofacial Pathologists” (IAOMP). The publication of JOMFP was started in the year 1993. The journal publishes papers on a wide spectrum of topics associated with the scope of Oral and Maxillofacial Pathology, also, ensuring scientific merit and quality. It is a comprehensive reading material for the professionals who want to upgrade their diagnostic skills in Oral Diseases; allows exposure to newer topics and methods of research in the Oral-facial Tissues and Pathology. New features allow an open minded thinking and approach to various pathologies. It also encourages authors to showcase quality work done by them and to compile relevant cases which are diagnostically challenging. The Journal takes pride in maintaining the quality of articles and photomicrographs.